Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 15/20 | 0.61 |
| ▸ | HTR2C | P28335 | 14/20 | 0.61 |
| ▸ | HTR2B | P41595 | 8/20 | 0.61 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17986330 | 0.91 | HTR2C (0.49) | HTR2AHTR2CHTR2BACACBACACA | |
| SCHEMBL17986423 | 0.89 | HTR2A (0.60) | HTR2AHTR2CHTR2BDRD2SUV39H2 | |
| SCHEMBL17986441 | 0.89 | HTR2C (0.59) | HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL17985450 | 0.89 | HTR2C (0.64) | HTR2AHTR2CHTR2B | |
| SCHEMBL17986694 | 0.87 | HTR2C (0.61) | HTR2AHTR2CHTR2BDRD2SUV39H2 | |
| SCHEMBL17986689 | 0.87 | HTR2C (0.64) | HTR2AHTR2CHTR2B | |
| SCHEMBL17985451 | 0.87 | HTR2A (0.43) | HTR2AHTR2CHTR2BACACBACACA | |
| SCHEMBL17962713 | 0.85 | HTR2A (0.64) | HTR2AHTR2CHTR2B | |
| SCHEMBL17986442 | 0.80 | HTR2C (0.47) | HTR2AHTR2CHTR2B | |
| SCHEMBL17986411 | 0.80 | HTR2C (0.47) | HTR2AHTR2CHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250549-B1 | CYCLOPROPYLMETHANAMINES AS SELECTIVE 5-HT(2C) RECEPTOR AGONISTS | UNIV ILLINOIS (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-107810175-B | Cyclopropylmethylamines as selective 5-HT (2C) receptor agonists | 伊利诺伊大学评议会 | 2021-06-15 | — | — | CN | disclosed |
| US-10407381-B2 | Cyclopropylmethanamines as selective 5-HT(2C) receptor agonists | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-09-10 | — | — | US | disclosed |
| WO-2016123164-A1 | CYCLOPROPYLMETHANAMINES AS SELECTIVE 5-HT(2C) RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407381-B2 | Cyclopropylmethanamines as selective 5-HT(2C) receptor agonists | HTR2C, HTR2A, HTR1A | HTR2A 2/4885HTR2C 1/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.